Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2013 | 10:15am CET

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:
www.drreddys.com

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com/ +91-40-66834297
Saunak Savla at saunaks@drreddys.com/ +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

Media:
S Rajan at rajans@drreddys.com/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DR.REDDY'S LABORATORIES LT
02/22 DR REDDY LABORATORIES : APOLLO HOSPITALS, Dr REDDY'S AMONG 15 FDI PLANS CLEARED
02/17 DR REDDY LABORATORIES : US COURT RULING GOES AGAINST Dr REDDY'S
02/17 DR REDDY LABORATORIES : Drl gets unfavourable patent ruling in us court
02/16 DR REDDY LABORATORIES : Aurobindo recall drugs from us
02/11 DR REDDY LABORATORIES : Launches generic drugs in france
02/08 DR REDDY LABORATORIES : . Reddy's expands commercial operations in Europe
02/06 DR REDDY LABORATORIES : . Reddy’s Q3 and 9M FY17 Financial Results
02/06 DR REDDY LABORATORIES : Q3 PROFIT DOWN 19% TO Rs470 CRORE
02/04 DR REDDY LABORATORIES : . Reddy’s Q3 and 9M FY17 Financial Results
02/01 Nifty above 8650, Sensex up over 300 pts as markets rejoice Budget
More news
Sector news : Pharmaceuticals - NEC
12:59a Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
02/23DJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/22 Momenta Delay Means Race For Copaxone Generic Is On
02/05 Dr. Reddy's reports FQ3 results
02/01 Teva's $1bn Copaxone Blow
02/01 Generic competitors to Teva's Copaxone see no rationale for delaying market e..
01/24 FDA rejection of Mezzion's marketing application for ED candidate udenafil pr..
Advertisement
Financials ( INR)
Sales 2017 144 410 M
EBIT 2017 18 005 M
Net income 2017 14 352 M
Debt 2017 13 381 M
Yield 2017 0,62%
P/E ratio 2017 33,18
P/E ratio 2018 21,07
EV / Sales 2017 3,41x
EV / Sales 2018 2,92x
Capitalization 478 342 M
More Financials
Chart DR.REDDY'S LABORATORIES LT
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Full-screen chart
Technical analysis trends DR.REDDY'S LABORA...
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 44
Average target price 3 196  INR
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DR.REDDY'S LABORATORIE..-5.20%7 196
JOHNSON & JOHNSON3.74%325 158
ROCHE HOLDING LTD.5.98%210 992
PFIZER INC.3.42%203 836
NOVARTIS AG3.51%202 566
MERCK & CO., INC.10.91%180 014
More Results